MedDataX Logo

Radiomics Analysis of Focal Liver Lesions Based on Contrast-Enhanced Ultrasound Imaging

NCT ID: NCT04682886

Last Updated: 2020-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Contrast-enhanced ultrasound (CEUS) substantially improves the potential of ultrasound (US) for the identification and characterization of focal liver lesions (FLLs). Compared to contrasted-enhanced MRI and CT, it has some unique advantages, such as the absence of ionizing radiation, and easy operability and repeatability. However, the efficacy of CEUS in diagnosing liver lesions is challenged by several factors including being highly dependent on doctor's experience, low signal-to-noise ratio, and low interobserver agreement. Therefore, it is a beneficial attempt to construct an intelligent CEUS diagnosis system using digital information technology. This study aims to collect standard data of CEUS cines recordings and develop deep learning model for accurate segmentation, detection and classification of liver lesions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Focal Liver Lesions Contrast-enhanced Ultrasound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

diagnosis

there is no intervention diagnosis or treatment for patients

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients with a solid liver tumor visible during routine ultrasound and received CEUS.
2. disease history and standard of reference of the lesions can be acquired

Exclusion Criteria

1. hypersensitivity for ultrasound contrast media
2. pregnant or lactating patients
3. previously treated lesions or local relapse from previously treated lesions
4. diffuse tumors
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ping Liang

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ping Liang

Prof

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jie Yu, Dr

Role: CONTACT

Phone: 15901417963

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jie Yu, Doctor

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Wu J, Liu S, Zhang Y, Ding W, Zhao Q, Wang Y, Xiao F, Yu X, Xie X, Liu S, Zhao J, Liao J, Yu J, Liang P. Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma and Associated Prognosis Using Contrast-enhanced US and Clinical Features. Radiol Imaging Cancer. 2025 Jul;7(4):e240419. doi: 10.1148/rycan.240419.

Reference Type DERIVED
PMID: 40607931 (View on PubMed)

Ding W, Meng Y, Ma J, Pang C, Wu J, Tian J, Yu J, Liang P, Wang K. Contrast-enhanced ultrasound-based AI model for multi-classification of focal liver lesions. J Hepatol. 2025 Aug;83(2):426-439. doi: 10.1016/j.jhep.2025.01.011. Epub 2025 Jan 21.

Reference Type DERIVED
PMID: 39848548 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

82030047

Identifier Type: -

Identifier Source: org_study_id